Takeda Chemical Industries, Inc.

Matsushita Electric Works, Ltd.

Hisamitsu Pharmaceutical Company, Inc.

Wako Pure Chemical Industries, Inc.

Hiroaki Okada

Yasuaki Ogawa

Takatsuka Yashiki

Shinya Murase

Hiroyuki Inoue

Teruaki Komatsu

Katsumi Iga

Yutaka Yamagata

Nobuteru Maekawa

Masayuki Sagawa

Michimasa Tsuzaki

Yayoi Inoue

Yayoi Douken

Yuri Sakai

Masaki Yamamoto

Shigeru Kamei

Tsutomu Miyagawa

Junji Imai

Narimasa Iwamoto

Satoshi Iinuma

Toshio Yoshioka

Katsuyoshi Shimoda

Akihiro Yamada

Yasutaka Igari

Shoji Kishimoto

Shin-Ichiro Hirai

Yasuyuki Suzuki

Kazuhiro Saito

Kazumichi Yamamoto

Iwao Yamazaki

Yoshihiro Shogaki

Yukihiro Matsumoto

Shigeo Yanai

Hiroshi Fujisawa

Katsuichi Sudo

Masaru Yoshida

Yasuichi Kinekawa

Toshiro Heya

Satoru Tanaka

Makoto Fukuta

Jun Tokuda

Toshifumi Sakamoto

Nobuteru Maegawa

Masahiko Fujita

Tsugio Shimamoto

Yasumoto Miura

There is provided wiring device for optical fiber capable of increasing the performance of construction work. A coveris disposed in an aperture formed at front surface of the plug receptacle main body, the upper end thereof is rotatably supported to the plug receptacle main body, and a receptacleis attached to the rear surface side of the cover. The receptaclehas a plug connection hole facing an outer surface side of a building at least at a used state and a plug connection portion into which a first optical-fiber plug being attached to the optical fiber cable wired to the inside of the building is inserted and connected, and optically connects the first optical fiber being connected to the plug connection portion and a second optical-fiber plug inserted from the outer surface side of the building through the plug connection hole. A notchfor inserting the first optical-fiber plug is formed at a sidewallof the plug receptacle main bodywhich is located in the inserting direction of the optical fiber plug inserted and connected to the plug connection portion.

Wiring device for optical fiber

Disclosed is a sustained-release preparation comprising 1) a polymer of lactic acid having a weight-average molecular weight of about 25,000 to about 60,000 and 2) a physiologically active substance, and which releases the physiologically active substance over a period of at least about 5 months; the sustained-release preparation shows an almost continuous zero order release of the physiologically active substance over a period of as long as about 5 months.

Sustained-release preparation capable of releasing a physiologically active substance

To provide a practical matrix for iontophoresis with markedly improved drug availability. A system for iontophoreses, which comprises an anode side matrix and a cathode side matrix, wherein the anode side matrix contains a cationized drug and the cathode side matrix contains a water soluble acidic substance. A matrix for iontophoreses comprising a drug reservoir containing a drug, the drug reservoir having a thickness of less than 0.05 mm. Iontophoresis using the iontophoretic matrix of the present invention makes it possible to administer a drug to the body at high availability.

Matrix for iontophoreses

A thermoelectric module is capable of successfully reducing the heat stress for increased reliability. The module includes a plurality of thermoelectric chips of P-type and N-type arranged in a matrix between sets of first and second contacts to form a series electrical circuit. The chips are arranged to give at least three chip arrays each having a limited number of the chips. A first carrier is provided on one side of the chips to carry the first contacts and to include first bridges each integrally joining two adjacent first contacts to define first discrete couples for electrical connection of the chips in each chip array. The first carrier further includes at least two inter-array bridges which are solely responsible for electrical interconnection between the adjacent chip arrays. On the opposite side of the chips, there are formed a plurality of second bridges each integrally joining the two adjacent second contacts to give second discrete couples for electrical connection of the two adjacent chips in each of the chip arrays. Thus, the inter-array bridges are formed only on one side of the chips for interconnection of the first contacts between the adjacent chip arrays. Therefore, the heat stress applied to the end of the chip array where the two adjacent chip arrays are interconnected can be well relieved on the side of the second contacts in which the second discrete couples are kept totally isolated from each other.

Thermoelectric module with interarray bridges

Thermoelectric module and a method of fabricating the same

According to a first embodiment, there is provided a sustained-release preparation comprising a water-insoluble or slightly water-soluble polyvalent metal salt of a water-soluble physiologically active substance which is not an endothelin antagonist, and a biodegradable polymer. The sustained-release preparation of the first embodiment is highly efficient in incorporating the water-soluble physiologically active substance and suppresses the initial burst of the water-soluble physiologically active substance. The sustained-release preparation of the present invention is capable of releasing the water-soluble physiologically active substance while retaining its bioactivity after administration in vivo. Furthermore, the water-soluble physiologically active substance in the sustained-release preparation is kept stable for a long period of time, with little loss of bioactivity. According to a second embodiment, there is provided a sustained-release preparation comprising an anti-endothelin substance and a biodegradable polymer. The sustained-release preparation of the present invention sustainedly releases an anti-endothelin substance, serving well in the treatment of endothelin-associated diseases.

Sustained-release preparation

Disclosed is a method of producing a sustained-release preparation for injection, which comprises adding to microspheres which are obtained from w/o emulsion with a solution containing a physiologically active peptide as an internal aqueous phase and a solution containing a polylactic acid having a weight-average molecular weight of about 5,000 to about 25,000 as an oil phase, a sugar in an amount of about 2 to about 60% (w/w) relative to the microspheres; freeze drying and subsequent heating at the temperature ranging from the glass transition temperature of the microspheres to the temperature which is higher by about 20&deg; C. than the glass transition temperature for about 24 to about 120 hours; and the method of the present invention suppresses microsphere particle aggregation during production process, makes it possible to almost perfectly remove the water and organic solvent in microspheres, and yields microspheres having good dispersibility and storage-stability.

Production of sustained-release preparation for injection

Sustained-release preparation capable of releasing a physiologically

Method of fabricating a thermoelectric module

Peltier module

This invention provides a microcapsule designed for zero order release of a physiologically active polypeptide over a period of at least two months, which is produced by preparing a water-in-oil emulsion comprising an inner aqueous layer containing about 20 to 70% (w/w) of said polypeptide and an oil layer containing a copolymer or homopolymer having a weight-average molecular weight of 7,000 to 30,000, wherein the composition ratio of lactic acid/glycolic acid in the copolymer or homopolymer is 80/10 to 100/0, and then subjecting said water-in oil emulsion to microencapsulation.

Prolonged release microcapsules

A parenteral pharmaceutical preparation comprises a matrix containing a physiologically active peptide or protein and a polyglycerol diester of a saturated fatty acid, and the matrix is in a solid form at room temperature. The molecular weight of the physiologically active peptide or protein is 2,000 dalton or more. The saturated fatty acid includes fatty acids having about 16 to 30 carbon atoms such as palmitic acid, stearic acid, etc. The matrix may be in a pillar or granular form. The parenteral pharmaceutical preparation can be used as an injectable solid administered subcutaneously or intramuscularly (for example, a pellet or tablet for implantation), a suppository or the like, and can release the physiologically active peptide or protein sustainedly for a prolonged period of one week or more.

Sustained releasable parenteral pharmaceutical preparations and method

The present invention relates to a microcapsule containing TRH, its analog or a salt thereof and a method of producing the same which attains the release of the active ingredient stably for a prolonged period of time with high rates of incorporation of the active ingredient thereinto and with little possibility of excessive initial release or burst.

Encapsulation of TRH or its analog

A microcapsule produced by preparing a water-in-oil emulsion comprising an inner aqueous layer containing said water-soluble drug and a drug retaining substance therefor and an oil layer containing a polymer substance, then thickening or solidifying said inner aqueous layer to a viscosity of not lower than about 5000 centiposes and finally subjecting the resulting emulsion to in water drying gives prolonged release of water-soluble drug.

Method for producing microcapsule

Growing community of inventors

Osaka, Japan

Hiroaki Okada